Mifepristone: Reflections on its Early Clinical Development for Medical Abortion

Area of Science:

• Pharmacology
• Reproductive Medicine
• Endocrinology

Background:

• Mifepristone (RU-486) is a significant progesterone antagonist.
• Initial research focused on its antiglucocorticoid properties.
• Its antiprogesterone effects were later recognized, leading to pregnancy termination studies.

Purpose of the Study:

• To review the development of mifepristone for pregnancy termination.
• To highlight the author's contributions to its early clinical use.
• To discuss the limited attention given to its broader therapeutic applications.

Main Methods:

• Literature review of mifepristone's development.
• Author's personal reflections on early clinical trials.
• Analysis of research trends concerning mifepristone.

Main Results:

• Mifepristone's efficacy in pregnancy termination was established.
• Early research prioritized its glucocorticoid receptor antagonist role.
• The article details the pathway to its use as an abortifacient.

Conclusions:

• Mifepristone is a proven agent for pregnancy termination.
• Further exploration of mifepristone's wider therapeutic potential is warranted.
• The historical development highlights a shift in research focus from antiglucocorticoid to antiprogesterone activity.